Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Nasal Mucosa-Derived Extracellular Vesicles as a Systemic Antiaging Intervention

Shi W., Bian L., Yu M., Wang J., Gao M., Shen L.

Animal Study on Face & Skin, Hip, Systemic / IV, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adv Sci (Weinh) (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41271567
PMCID
PMC12850021
DOI
10.1002/advs.202511372
Citations
1

Abstract (original English)

Aging impairs tissue function and regenerative capacity across multiple organs. This study demonstrates that extracellular vesicles derived from human nasal mucosa (nmEVs) exert systemic antiaging effects in aged mice. Treatment with nmEVs improves cognitive performance and alters hippocampal aging signatures related to synaptic signaling and the regulation of neuroplasticity. In parallel, transcriptomic analysis of five major aging-sensitive organs reveals that nmEVs broadly ameliorate age-associated transcriptional changes, notably by restoring circadian rhythmicity and suppressing cellular senescence-related pathways. At the cellular level, nmEVs alleviate senescence phenotypes in aged human bone marrow mesenchymal stem cells, restore proliferation and osteogenic capacity, and reactivate core clock gene expression. These effects are accompanied by modulation of the p53 pathway, suggesting its involvement in nmEV-mediated rejuvenation. Importantly, lacking the need for cell isolation and ex vivo expansion, nmEVs offer a practical, age-independent source of extracellular vesicles with high clinical accessibility. Together, these findings support the translational potential of nmEVs as a multifaceted therapeutic candidate for systemic aging intervention.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Nasal MucosaMesenchymal Stem CellsAnimalsMice, Inbred C57BLHumansMiceAgingMaleExtracellular VesiclesCellular Senescence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research